

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 519  
(A-22)

Introduced by: Association for Clinical Oncology

Subject: Advanced Research Projects Agency for Health (ARPA-H)

Referred to: Reference Committee E

---

1 Whereas, The current biomedical and cancer research enterprise has led to the discovery of  
2 innovative new treatments for all areas of healthcare through basic and translational research  
3 and clinical trials;  
4

5 Whereas, COVID-19 has disrupted biomedical and cancer research and continues to threaten  
6 research progress;  
7

8 Whereas, President Biden has called for a major investment in cutting edge/innovative federal  
9 research with the establishment of the Advanced Research Projects Agency for Health (ARPA-  
10 H);  
11

12 Whereas, Efforts to establish ARPA-H should ensure sustained and dedicated funding to  
13 achieve impactful translational research;  
14

15 Whereas, Any reform to the biomedical research enterprise and health innovation efforts should  
16 not impact the current or future resources of existing research enterprises; therefore be it  
17

18 RESOLVED, That our American Medical Association urge Congress and the Administration to  
19 ensure that while providing adequate funding for the promising research conducted at Advanced  
20 Research Projects Agency for Health (ARPA-H), it also provides robust annual baseline  
21 increases in appropriations for other research agencies, centers, and institutes, including, but  
22 not limited to, the NIH and NCI. (Directive to Take Action)

Fiscal Note: Not yet determined

Received: 05/11/22

## RELEVANT AMA POLICY

### Importance of Clinical Research H-460.930

(1) Given the profound importance of clinical research as the transition between basic science discoveries and standard medical practice of the future, the AMA will a) be an advocate for clinical research; and b) promote the importance of this science and of well-trained researchers to conduct it.

(2) Our AMA continues to advocate vigorously for a stable, continuing base of funding and support for all aspects of clinical research within the research programs of all relevant federal agencies, including the National Institutes of Health, the Agency for Healthcare Research and Quality, the Centers for Medicare & Medicaid Services, the Department of Veterans Affairs and the Department of Defense.

(3) The AMA believes it is an inherent obligation of capitation programs and managed care organizations to invest in broad-based clinical research (as well as in health care delivery and outcomes research) to assure continued transition of new developments from the research bench to medical practice. The AMA strongly encourages these groups to make significant financial contributions to support such research.

(4) Our AMA continues to encourage medical schools a) to support clinical research; b) to train and develop clinical researchers; c) to recognize the contribution of clinical researchers to academic medicine; d) to assure the highest quality of clinical research; and e) to explore innovative ways in which clinical researchers in academic health centers can actively involve practicing physicians in clinical research.

(5) Our AMA encourages and supports development of community and practice-based clinical research networks.

Citation: CSA Rep. 2, I-96; Reaffirmed: CSA Rep. 13, I-99; Reaffirmation A-00; Reaffirmed: CME Rep. 4, I-08; Modified: CSAPH Rep. 01, A-18